Does Rallies show 13F holders for NVS?

Yes. Rallies tracks hedge fund and 13F ownership data for NVS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVS. It does not provide personalized investment advice.

NVS (Novartis AG) Stock Analysis - Hedge Fund Holdings

Novartis AG (NVS) is a publicly traded Healthcare sector company. As of May 20, 2026, NVS trades at $151.00 with a market cap of $284.59B and a P/E ratio of 0.00. NVS moved -0.01% today. Year to date, NVS is +8.59%; over the trailing twelve months it is +35.89%. Its 52-week range spans $96.06 to $170.46. Analyst consensus is buy with an average price target of $167.22. Rallies surfaces NVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NVS stock?

Hedge funds tracked by Rallies that own NVS include GQG Partners, Maverick Capital, Mangrove Partners, A16Z Perennial, and Chilton Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Novartis AG.

NVS Key Metrics

Key financial metrics for NVS
Metric	Value
Price	$151.00
Market Cap	$284.59B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	4.74%
52-Week High	$170.46
52-Week Low	$96.06
Volume	1.11M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding NVS

GQG Partners holds 2.45M shares of NVS, changed -22.51% as of Mar 31, 2026.
Maverick Capital holds 15.25K shares of NVS, changed +37.70% as of Mar 31, 2026.
Mangrove Partners holds 7.92K shares of NVS, changed +0.00% as of Dec 31, 2024.
A16Z Perennial holds 2.62K shares of NVS, changed +0.00% as of Mar 31, 2026.
Chilton Investment holds 2.25K shares of NVS, changed -56.29% as of Mar 31, 2026.

Latest NVS News

Novartis Partners on Brain Transporter Tech as Leqembi Sales Expected at $900M — May 20, 2026
Novartis to outsource 35% of API, 25% of biologics manufacturing, saves $120 M — May 12, 2026
Novartis Secures Three-Part Bond Funding in Record €31B European Debt Sale — May 6, 2026
Novartis jumps as Q1 update reassures on guidance and accelerating key-drug growth — Apr 30, 2026
Novartis slides as Q1 results miss estimates amid Entresto generic pressure — Apr 28, 2026

NVS Analyst Consensus

5 analysts cover NVS: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $167.22.

Common questions about NVS

Who owns NVS stock?: Hedge funds tracked by Rallies that own NVS include GQG Partners, Maverick Capital, Mangrove Partners, A16Z Perennial, and Chilton Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Novartis AG.
Does Rallies show 13F holders for NVS?: Yes. Rallies tracks hedge fund and 13F ownership data for NVS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVS. It does not provide personalized investment advice.